Clearside Biomedical

$0.72
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0736 (-9.45%) Today
+$0.015 (2.13%) As of 4:02 PM EDT after-hours

Why Robinhood?

You can buy or sell CLSD and other stocks, options, ETFs, and crypto commission-free!

About CLSD

Clearside Biomedical, Inc. Common Stock, also called Clearside Biomedical, is a clinical stage biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. Read More Its pipeline includes Suprachoroidal CLS-TA, Suprachoroidal, Suprachoroidal CLS-TA, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.

Employees
50
Headquarters
Alpharetta, Georgia
Founded
2011
Market Cap
29.40M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.10M
High Today
$0.7984
Low Today
$0.7043
Open Price
$0.75
Volume
1.18M
52 Week High
$7.07
52 Week Low
$0.68

Collections

CLSD News

ReutersAug 10

Edited Transcript of CLSD earnings conference call or presentation 7-Aug-19 8:30pm GMT

71

CLSD Earnings

-$0.75
-$0.55
-$0.35
-$0.15
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Nov 6, After Hours

More CLSD News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.